Abemaciclib Monotherapy Shows Promise After CDK4/6 Inhibitor Failure in HR+/HER2- Breast Cancer
Key Insights
Approximately 33% of patients with HR (search)-positive, HER2 (search)-negative breast cancer (search) derived clinical benefit from abemaciclib monotherapy after disease progression on prior CDK4/6 (search) inhibitor therapy in the retrospective rAMBER study.
The median duration of treatment with abemaciclib was 4.0 months following disease progression on palbociclib-based treatment, with one patient achieving partial response and seven experiencing stable disease.
Genomic analysis revealed that RB1 (search) alterations were associated with acquired or intrinsic resistance to abemaciclib, while ESR1 (search) alterations were found across all biopsy phenotypes.
Abemaciclib monotherapy demonstrated clinical benefit in approximately one-third of patients with hormone receptor-positive, HER2 (search)-negative breast cancer (search) following disease progression on prior CDK4/6 (search) inhibitor therapy, according to data from the retrospective rAMBER study presented at the 2025 San Antonio Breast Cancer Symposium.
The study evaluated 30 patients across four academic centers who received abemaciclib monotherapy after experiencing disease progression on CDK4/6 (search) inhibitor-based therapy. Despite prior treatment failure, 33% of patients derived benefit from abemaciclib, with the agent proving tolerable for more than 180 days.
Treatment Outcomes and Duration
The median duration of treatment with abemaciclib was 4.0 months (95% CI, 2.8-13.9) following disease progression on palbociclib-based treatment. The median number of intervening lines of therapy between palbociclib and abemaciclib was 2.
Most patients (23 of 30) remained on abemaciclib until either disease progression or death, while the remaining 7 patients discontinued therapy due to adverse effects. Among the evaluable responses, one patient achieved a partial response with abemaciclib, seven patients experienced stable disease, and eight had disease progression.
Study Design and Patient Population
The study authors collected retrospective patient data at four academic centers: Massachusetts General Hospital, Barnes-Jewish Hospital, University of Pittsburgh Medical Center, and Moffitt Cancer Center. They identified patients with metastatic HR (search)-positive, HER2 (search)-negative breast cancer (search) who received abemaciclib monotherapy after experiencing disease progression on CDK4/6 (search) inhibitor-based therapy.
Patients were divided into two subgroups: those who received sequential CDK4/6 (search) inhibitor-based therapy (n = 6) and those who received nonsequential CDK4/6 inhibitor-based therapy (n = 24). Data were collected via Institutional Review Board-approved protocols, with examination of patient demographics and clinical outcomes.
Genomic Insights and Resistance Mechanisms
A genomic exploration was performed in which each biopsy was assigned a phenotype based on best clinical response and duration of response in relation to biopsy timing. Phenotypes were defined by sensitivity, acquired resistance, or intrinsic resistance.
Findings from genomic analysis of 23 biopsies showed that RB1 (search) alterations were associated with acquired or intrinsic resistance to abemaciclib treatment. ESR1 (search) alterations were found across all biopsy phenotypes, suggesting these mutations may not be predictive of response to sequential CDK4/6 (search) inhibitor therapy.
"Preliminary genetic analyses revealed enrichment in RB1 (search) alterations in patients with rapid disease progression," the study authors noted in their conclusion.
Clinical Context and Significance
CDK4/6 (search) inhibitors have become the standard of care for patients with advanced HR (search)-positive, HER2 (search)-negative breast cancer (search). However, uncertainty has remained regarding the efficacy of CDK4/6 inhibitor re-introduction after progression on these agents.
"rAMBER is the first [study] to evaluate the effectiveness of abemaciclib monotherapy after progression on [a] CDK4/6 (search) inhibitor, offering new perspectives on the role of sequential CDK4/6 therapies," wrote study author Sahar Shahamatdar, MD, PhD, an internal medicine resident physician at Massachusetts General Hospital in Boston, and her coauthors.
The FDA approved abemaciclib in combination with an aromatase inhibitor for the frontline treatment of postmenopausal women with HR (search)-positive, HER2 (search)-negative advanced or metastatic breast cancer (search) in February 2018. This approval was supported by data from the phase 3 MONARCH 3 trial, which showed that patients who received abemaciclib experienced a median progression-free survival of 28.2 months compared to 14.8 months among those who received placebo.